Overview

MetrioPharm Develope Pipeline

News

MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19 - 2022-Mar-02

The objective of the study is to determine whether the anti-inflammatory effect of MP1032 can slow the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease and alleviate COVID-19 symptoms.

» more

Investor Relations

Investor Relations News QI 2022 - 2022-Mar-31

Outlook by the Chairman of the Board Rudolf Stäger

» more

Blog

Read our latest blog post: - 2021-May-12

Phase II Clinical Trial in COVID-19

» more

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact
Blog

Social

  

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Bleicherweg 10
8002 Zurich

Phone: +41 44 562 03 35

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

Imprint
Privacy policy
Sitemap